Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
https://www.fool.com/investing/2024/02/18/novo-nordisk-has-more-than-ozempic-one-of-its/?source=iedfolrf0000001
Feb 18, 2024 - It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too.
0
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
https://www.zacks.com/stock/news/2235993/new-to-investing-this-1-medical-stock-could-be-the-perfect-starting-point?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2235993
Mar 05, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
0
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322
Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
0
Top Research Reports for Novo Nordisk, Tesla & Airbnb
https://www.zacks.com/commentary/2239296/top-research-reports-for-novo-nordisk-tesla-airbnb?cid=CS-ZC-FT-research_daily-2239296
Mar 12, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Tesla, Inc. (TSLA) and Airbnb, Inc. (ABNB).
0
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2241407/why-novo-nordisk-nvo-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2241407
Mar 15, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
https://www.fool.com/investing/2024/03/22/with-shares-near-all-time-highs-is-it-a-buy/?source=iedfolrf0000001
Mar 22, 2024 - The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.
0
Wall Street Awaits Consumer Confidence Data
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
0
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
https://www.zacks.com/stock/news/2246931/viking-vktx-up-17-on-encouraging-oral-obesity-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246931
Mar 27, 2024 - Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
0
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
https://www.fool.com/investing/2024/03/31/diversifying-into-this-key-market-is-1-more-reason/?source=iedfolrf0000001
Mar 31, 2024 - The semaglutide maker just announced a strategic acquisition that will be a green flag for its future value.
0
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375
Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
0